Stem cell transplantation in multiple myeloma: Impact of response failure with thalidomide or lenalidomide induction

Blood

Volumn 115, Issue 12, 2010, Pages 2348-2353

  Gertz, Morie A ^a   Kumar, Shaji ^a   Lacy, Martha Q ^a   Dispenzieri, Angela ^a   Dingli, David ^a   Hayman, Suzanne R ^a   Buadi, Francis K ^a   Hogan, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CANCER RELAPSE; CHROMOSOME 1; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; DISEASE FREE SURVIVAL; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77950607507     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-235531     Document Type: Article

References (30)

1. Vandenberghe EA, Goldstone AH. Autologous stem cell transplants in lymphomas. Ann Med. 1996;28(2):137-143.
2. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol. 1997;34(1 suppl 1):61-66.
3. Kyle RA. Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. Clin Lymphoma. 2001;2(1):21-28.
4. Bladé J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol. 2000;39(7):843-847.
5. Tricot G, Jagannath S, Vesole DH, et al. Hematopoietic stem cell transplants for multiple myeloma. Leuk Lymphoma. 1996;22(1-2):25-36.
6. Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells. 1995;13(suppl 2):118-121.
7. Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1994;13(5-6):479-484.
8. Barlogie B, Alexanian R, Dicke KA, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood. 1987;70(3):869-872.
9. Kumar S, Lacy MQ, Dispenzieri A, et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant. 2004;34(2):161-167.
10. Vesole DH, Crowley JJ, Catchatourian R, et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol. 1999;17(7):2173-2179.
11. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30(10):673-679.
12. Sirohi B, Powles R, Cavanagh J, et al. Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy. Hematology. 2007;12(2):113-115.
13. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341.
14. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma [erratum in: Haematologica. 2008;93(3):480]. Haematologica. 2008;93(1):124-127.
15. Rosiñol L, Oriol A, Mateos MV, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25(28):4452-4458.
16. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035-2042.
17. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008;14(7):795-798.
18. Barlogie B, Alexanian R, Smallwood L, et al. Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood. 1988;72(6):2015- 2019.
19. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883.
20. Lane SW, Gill D, Mollee PN, Rajkumar SV. Role of VAD in the initial treatment of multiple myeloma [letter]. Blood. 2005;106(10):3674.
21. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35-39.
22. Breitkreutz I, Lokhorst HM, Raab MS, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007;21(6):1294-1299.
23. Badros A, Goloubeva O, Fenton R, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma. 2006;7(3):210-216.
24. Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia. 2008;22(7):1343-1353.
25. Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138(3):330-337.
26. Anderson KC. The role of immunomodulatory drugs in multiple myeloma. Semin Hematol. 2003;40(4 suppl 4):23-32.
27. Kumar SK, Dingli D, Dispenzieri A, et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant. 2008;41(12):1013-1019.
28. Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-5782.
29. Kumar S, Flinn IW, Noga SJ, et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multicenter EVOLUTION study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):41. Abstract 93
30. Kumar S, Lacy MQ, Dispenzieri A, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant. 2004;34(6):485-490.